NEUROCRINE BIOSCIENCES, INC.
In the published model solve dated 2026-Q2, anchored at $161.48, NEUROCRINE BIOSCIENCES, INC. (NBIX) is priced for +10.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
Neurocrine Biosciences is a profitable, net-cash biotech built around INGREZZA, its tardive dyskinesia drug, which is about 88% of revenue, with the newer CRENESSITY adding roughly 11%. Trailing operating margin is about 25%, and the most recent quarter put net product sales above $800 million, up 44% year over year. At $158.30 (June 27, 2026) the price pays about 26x company-wide operating income, which implies operating growth near 18% per year for five years. The static valuation families ca
Is NBIX overvalued? See what's priced in →
673 institutional managers reported holding NBIX in 13F filings for the quarter ended 2026-03-31. Together they hold about 91% of the company; the top 10 hold 48%. 70 opened new positions that quarter. Held by BlackRock, Vanguard Group, Dodge & Cox, among others. On the short side, 5.7M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
NBIX's share count grew 6.2% over the past five years even with $521.70M spent on repurchases. It pays no dividend. Cash returned over the past three years: $521.70M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at NBIX over the trailing three years. Absence is a fact about the company, not a signal. 20 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
NBIX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-02 | +2.2% | +6.3% |
| 2023-11-01 | +4.1% | +19.0% |
| 2024-02-10 | -6.0% | +1.8% |
| 2024-05-02 | +1.7% | -1.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
NBIX's latest 8-K filings: 2026-07-30 (items 2.02, 9.01); 2026-05-28 (items 5.02, 5.07); 2026-05-18 (items 1.01, 2.01, 2.03, 7.01, 9.01); 2026-05-05 (items 2.02, 9.01); 2026-04-06 (items 1.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.